NICE Referral Criteria May Miss Younger Women at Elevated Breast Cancer Risk

Family History Alone Leaves a Wide Detection Gap

Referral criteria used in English primary care may identify only a small fraction of women younger than 50 years who will develop breast cancer within the next decade, according to a new analysis published in the British Journal of Cancer.¹

Investigators compared current National Institute for Health and Care Excellence (NICE) family history–based referral criteria with BOADICEA, a multifactorial breast cancer risk model. The analysis included 1258 women aged 20 to 49 years from the Breast Cancer Now Generations Study who enrolled between 2004 and 2011; 392 developed invasive breast cancer or ductal carcinoma in situ during 10 years of follow-up. The sample was weighted to better represent the UK population.¹

Under the NICE approach, 1.4% of women would have met criteria for referral, capturing just 4.4% of those who developed breast cancer within 10 years. Full BOADICEA assessment would have classified 26.5% as above population-level risk and identified 34.8% of women who later developed breast cancer—approximately 8 times the case detection achieved by the NICE pathway.¹

Why Multifactorial Assessment Finds More Women

NICE guidance directs primary care clinicians to obtain first- and second-degree family histories and use defined family patterns to determine referral to secondary care or specialist genetics services.² Yet in the new study, 73% of women estimated to have above-population risk with the full model had no first- or second-degree family history of breast cancer.¹

BOADICEA broadens the lens by integrating detailed pedigree information with established hormonal, reproductive, lifestyle, and genetic factors, including a polygenic risk score.³ In the present analysis, versions of the model showed good discrimination for 10-year breast cancer status, with area-under-the-curve values ranging from 0.74 to 0.76, although risk was slightly underestimated overall.¹

The comparison should not be interpreted as evidence that population-wide BOADICEA testing is ready for immediate adoption. The full strategy would refer more than 1 in 4 women younger than 50, versus roughly 1 in 70 under NICE criteria. It also identified only about one-third of women who developed breast cancer. The investigators emphasized the need to evaluate feasibility, cost-effectiveness, equity, downstream harms, and service capacity before implementation.¹

Pharmacy Implications Extend Beyond Referral

For pharmacists, improved risk stratification could shift some breast cancer care upstream. NICE recommends enhanced surveillance for defined higher-risk groups and offers risk-reducing pharmacotherapy to eligible women after individualized discussion. Depending on menopausal status and clinical circumstances, options include tamoxifen or anastrozole, with raloxifene considered in some postmenopausal patients.²

Oncology and health-system pharmacists can support shared decision-making by explaining expected benefits, assessing contraindications and drug interactions, and counseling about adverse effects and adherence. They may also help build standardized referral and medication-management pathways if multifactorial assessment expands.

A Signal for Guideline Review, Not a Final Verdict

The study exposes a major sensitivity gap in a pathway anchored to family history, but it also quantifies the workload created by broader assessment. Prospective implementation studies should determine whether staged or digitally supported risk assessment can improve early detection and prevention without overwhelming primary care, genetics, imaging, and pharmacy services. Until then, the results provide a strong rationale to reassess how younger women are identified for breast cancer risk evaluation.

REFERENCES

1. Frost R, Ficorella L, Berrington de Gonzalez A, et al. Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care. Br J Cancer. Published online August 4, 2026. doi:10.1038/s41416-026-03547-2

2. National Library of Medicine. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE guideline CG164. Published June 25, 2013. Updated November, 2023. Accessed August 10, 2026. https://www.ncbi.nlm.nih.gov/books/NBK552606/

3. Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019;21(8):1708-1718. doi:10.1038/s41436-018-0406-9